Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

439 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer.
Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Wikström P, et al. Among authors: stattin p. Prostate. 1998 Sep 15;37(1):19-29. doi: 10.1002/(sici)1097-0045(19980915)37:1<19::aid-pros4>3.0.co;2-3. Prostate. 1998. PMID: 9721065
Modal DNA values and estramustine-binding protein (EMBP) as prognostic markers in prostatic cancer.
Nordgren H, Nilsson S, Eklöv S, Stattin P, Naining W, Heiden T, Bergkvist L, Karlberg L, Lundholm C, Harvig B, et al. Nordgren H, et al. Among authors: stattin p. Acta Oncol. 1991;30(2):211-4. doi: 10.3109/02841869109092353. Acta Oncol. 1991. PMID: 2029408
Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
Westin P, Stattin P, Damber JE, Bergh A. Westin P, et al. Among authors: stattin p. Am J Pathol. 1995 Jun;146(6):1368-75. Am J Pathol. 1995. PMID: 7778676 Free PMC article.
Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients.
Stattin P, Damber JE, Modig H, Bergh A. Stattin P, et al. Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):885-9. doi: 10.1016/0360-3016(96)00134-4. Int J Radiat Oncol Biol Phys. 1996. PMID: 8751397
p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer.
Stattin P, Bergh A, Karlberg L, Nordgren H, Damber JE. Stattin P, et al. Eur Urol. 1996;30(1):65-72. doi: 10.1159/000474147. Eur Urol. 1996. PMID: 8854070
Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival.
Stattin P, Damber JE, Karlberg L, Nordgren H, Bergh A. Stattin P, et al. Urol Res. 1996;24(5):257-64. doi: 10.1007/BF00304774. Urol Res. 1996. PMID: 8931289
Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.
Stattin P, Damber JE, Karlberg L, Bergh A. Stattin P, et al. J Urol. 1997 Jan;157(1):219-22. J Urol. 1997. PMID: 8976256
Prognostic factors in prostate cancer.
Stattin P. Stattin P. Scand J Urol Nephrol Suppl. 1997;185:1-46. Scand J Urol Nephrol Suppl. 1997. PMID: 9249905
Vascular density is a predictor of cancer-specific survival in prostatic carcinoma.
Lissbrant IF, Stattin P, Damber JE, Bergh A. Lissbrant IF, et al. Among authors: stattin p. Prostate. 1997 Sep 15;33(1):38-45. doi: 10.1002/(sici)1097-0045(19970915)33:1<38::aid-pros7>3.0.co;2-5. Prostate. 1997. PMID: 9294625
Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.
Stattin P, Bergh A, Karlberg L, Tavelin B, Damber JE. Stattin P, et al. Eur Urol. 1997;32(4):404-9. Eur Urol. 1997. PMID: 9412796 Clinical Trial.
439 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback